Roger L Albin

Feb 8, 2024 | thelancet.com | Roger L Albin

Richard M Carpiano and colleagues provide a useful summary of anti-vaccine activism in the USA. 1Carpiano RM Callaghan T DiResta R et al. Confronting the evolution and expansion of anti-vaccine activism in the USA in the COVID-19 era. Their policy prescriptions are sensible but are likely to fall short because they fail to confront a fundamental feature of anti-vaccine activism. Anti-vaccine activism is one of numerous right-wing initiatives defending free market fundamentalism.

Oct 10, 2023 | myumi.ch | James Burke |Kevin Kerber |Kenneth M. Langa |Roger L Albin

REQUIREMENTSYou must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information. Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

Oct 9, 2023 | n.neurology.org | James Burke |Kevin Kerber |Kenneth M. Langa |Roger L Albin

REQUIREMENTSYou must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information. Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

Jul 21, 2023 | n.neurology.org | James Burke |Kevin Kerber |Kenneth M. Langa |Roger L Albin

AbstractLecanemab, a novel amyloid-sequestering agent, recently received accelerated FDA approval for the treatment of mild Dementia due to Alzheimer Disease (AD) and Mild Cognitive Impairment (MCI). Approval was based on a large Phase 3 trial, Clarity, which demonstrated reductions in amyloid plaque burden and cognitive decline with lecanemab.